Holen Sie sich die Stockscreener-App
205.07
0.56%
-1.16
Handel nachbörslich:
206.00
0.93
+0.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$206.23
Offen:
$206.265
24-Stunden-Volumen:
27.97M
Relative Volume:
3.99
Marktkapitalisierung:
$362.60B
Einnahmen:
$61.16B
Nettoeinkommen (Verlust:
$4.19B
KGV:
86.84
EPS:
2.3614
Netto-Cashflow:
$17.82B
1W Leistung:
-6.65%
1M Leistung:
-8.78%
6M Leistung:
-7.82%
1J Leistung:
-3.25%
1-Tages-Spanne:
$203.06
$207.78
1-Wochen-Bereich:
$203.06
$224.37
52-Wochen-Spanne:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
205.07 | 362.60B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
906.70 | 809.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.37 | 566.92B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
183.60 | 284.73B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
114.18 | 282.30B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie Inc. $ABBV Shares Acquired by Procyon Advisors LLC - MarketBeat
MassMutual Private Wealth & Trust FSB Has $39.20 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
CWA Asset Management Group LLC Purchases 11,964 Shares of AbbVie Inc. $ABBV - MarketBeat
Aventura Private Wealth LLC Takes $2.14 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Stock Slides as Insider Selling Spooks Investors - TipRanks
AbbVie Inc. $ABBV Shares Sold by TruWealth Advisors LLC - MarketBeat
Neville Rodie & Shaw Inc. Has $23.31 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. (ABBV) one of the debt free halal stocks to buy? - MSN
If You Invested $1,000 in Abbvie Inc (ABBV) - Stock Titan
The Smartest Dividend ETF to Buy With $1,000 Right Now - The Motley Fool
Union Bancaire Privee UBP SA Boosts Stake in AbbVie Inc. $ABBV - MarketBeat
Park National Corp OH Sells 10,959 Shares of AbbVie Inc. $ABBV - MarketBeat
Hudson Bay Capital Management LP Buys 13,466 Shares of AbbVie Inc. $ABBV - MarketBeat
Coastline Trust Co Buys 10,492 Shares of AbbVie Inc. $ABBV - MarketBeat
Farmers National Bank Increases Stake in AbbVie Inc. $ABBV - MarketBeat
Alecta Tjanstepension Omsesidigt Buys 110,300 Shares of AbbVie Inc. $ABBV - MarketBeat
AIA Group Ltd Purchases 15,295 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform - Yahoo Finance
AbbVie (ABBV) looks to deepen its push into rapidly growing obesity-treatment market - MSN
Atopic Dermatitis Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie - Barchart
AbbVie (ABBV) Declines More Than Market: Some Information for Investors - Yahoo Finance
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AbbVie Inc (ABBV) Stock Price, Trades & News - GuruFocus
Buy Or Fear AbbVie Stock At $210? - Forbes
What’s Happening With AbbVie Stock? - Trefis
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
United Therapeutics or AbbVie: Which Stock Has More Upside? - Trefis
Stillwater Wealth Management Group Takes Position in AbbVie Inc. $ABBV - MarketBeat
Groupama Asset Managment Purchases 10,854 Shares of AbbVie Inc. $ABBV - MarketBeat
Investment Research Partners LLC Buys New Shares in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by CIBC Private Wealth Group LLC - MarketBeat
243,718 Shares in AbbVie Inc. $ABBV Bought by CIBC Bancorp USA Inc. - MarketBeat
Centaurus Financial Inc. Has $3.08 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Allworth Financial LP Acquires 30,124 Shares of AbbVie Inc. $ABBV - MarketBeat
Achmea Investment Management B.V. Has $84.36 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. Stock (ISIN: US00287Y1091) Faces Pressure Amid Recent Pullback: Key Drivers and Investor - AD HOC NEWS
Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback - Yahoo Finance
What's Going On With AbbVie Stock Today?AbbVie (NYSE:ABBV) - Benzinga
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MSN
AbbVie (NYSE:ABBV) Trading Down 5.1%Here's Why - MarketBeat
AbbVie (ABBV) Stock Drops 5% After FDA Approves J&J’s Competing Psoriasis Drug - CoinCentral
AbbVie (ABBV) Faces New Competition from J&J's Icotyde Approval - GuruFocus
AbbVie Inc. (ABBV) is attracting investor attention: Here is what you should know - MSN
J&J’s new psoriasis pill to rival AbbVie’s Skyrizi: BNP Paribas - Seeking Alpha
AbbVie (ABBV) slides as investors weigh policy-related pricing risk and recent financing activity - Quiver Quantitative
What triggered AbbVie shares' latest price pullback - Traders Union
AbbVie, Philip Morris among market cap stock movers on Wednesday - Investing.com
Weak momentum, oversold signals: AbbVie stock slides 3.70% - Traders Union
AbbVie Inc Stock (ABBV) Moved Down by 4.60% on Mar 18: A Full Analysis - TradingKey
AbbVie Stock: EPS Set to Jump 45% in 2026 as Skyrizi and Rinvoq Dominate IBD - TIKR.com
AbbVie Inc. $ABBV Shares Sold by Wilmington Savings Fund Society FSB - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):